

ICICI Prudential Nifty Pharma Index Fund

(An open ended Index scheme replicating Nifty Pharma Index)

Category
Index Schemes

Returns of ICICI Prudential Nifty Pharma Index Fund - Growth Option as on August 31, 2026

Particulars	1 Year		3 Years		5 Years		Since inception	
	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000
Scheme	23.87	12401.38	20.93	17692.59	-	-	21.42	20564.10
Nifty Pharma TRI (Benchmark)	25.29	12544.52	22.45	18371.86	-	-	23.19	21704.36
Nifty 50 TRI (Additional Benchmark)	-0.35	9964.59	8.99	12951.19	-	-	8.37	13481.17
NAV (Rs.) Per Unit (as on August 31,2026 : 20.5641)	16.5821		11.6230		-		10.00	

- Notes:
1. Different plans shall have different expense structure. The performance details provided herein are of ICICI Prudential Nifty Pharma Index Fund.
 2. The scheme is currently managed by Nishit Patel, Ashwini Bharucha & Venus Ahuja. Mr. Nishit Patel has been managing this fund since December 2022. Total Schemes managed by the Fund Manager are 58 (58 are jointly managed).
 3. Ms. Ashwini Bharucha has been managing this fund since Dec 24. Total Schemes managed by the Fund Manager are 57 (57 are jointly managed).
 4. Mr. Venus Ahuja has been managing this fund since Nov 25. Total Schemes managed by the Fund Manager are 57 (57 are jointly managed). Refer annexure at the following [link](#) for performance of other funds being managed by the fund managers.
 5. Date of inception: 14-Dec-22.
 6. As the Scheme has completed more than 3 year but less than 5 years, the performance details of since inception, 1 year and 3 years are provided herein.
 7. Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investment.
 8. Load (if any) is not considered for computation of returns.
 9. In case, the start/end date of the concerned period is a nonbusiness date (NBD), the NAV of the previous date is considered for computation of returns. The NAV per unit shown in the table is as on the start date of the said period
 10. NAV is adjusted to the extent of IDCW declared (if any) for computation of returns.
 11. The performance of the scheme is benchmarked to the Total Return variant of the Index.
 12. With effect from November 01, 2025, Mr. Venus Ahuja has been appointed as the fund manager under the scheme.

Scheme Details

Fund Managers : Nishit Patel (Managing this fund since December, 2022 & Overall 7 years of experience) Ashwini Bharucha (Managing this fund since Dec, 2024 & Overall 10 years of experience) Venus Ahuja (Managing this fund since Nov, 2025 & Overall 3 years of experience) (w.e.f. Nov 01, 2025)	Monthly AAM as on 31-Aug-26 : Rs. 151.94 crores Closing AUM as on 31-Aug-26 : Rs. 156.88 crores	Exit load: Nil
Indicative Investment Horizon: 5 years and above	Application Amount for fresh Subscription : Rs. 1000/- (plus in multiple of Re. 1)	Base Expense Ratio @@ : Other : 0.89% p. a. Direct : 0.32% p. a. For TER, Investor may refer to our website at https://www.icicpruamc.com/about-us/financials-&-disclosures?currentTabFilter=Total+Expense+Ratio&subCatTabFilter=Total+Expense+Ratio
Inception/Allotment date: 14-Dec-2022	Min.Addl.Investment : Rs. 1000/- and any amount thereafter	
NAV (As on 31-Aug-26): Growth Option : Rs. 20.5641 IDCW Option : 20.5642 Direct Plan Growth Option : Rs. 21.0563 Direct Plan IDCW Option : 21.0573		

Portfolio as on August 31, 2026

Company/Issuer	% to NAV	Top 7 Groups Exposure				
Equity Shares	99.93%	Group Name		Exposure (%)		
Pharmaceuticals & Biotechnology	99.93%	Sun Pharma		20.76		
• Sun Pharmaceutical Industries Ltd.	20.76%	Indian Private-Divis Laboratories Ltd.		11.88		
• Divi's Laboratories Ltd.	11.88%	Indian Private-Cipla Ltd.		7.83		
• Cipla Ltd.	7.83%	Indian Private-Laurus Labs Ltd.		7.36		
• Laurus Labs Ltd.	7.36%	Torrent		7.34		
• Torrent Pharmaceuticals Ltd.	7.34%	Dr. Reddy's		6.95		
• Dr. Reddy's Laboratories Ltd.	6.95%	Indian Private-Lupin Ltd		5.25		
• Lupin Ltd.	5.25%	Capital Line, CRISIL Research				
• Aurobindo Pharma Ltd.	4.69%	Tracking Difference Data (%) as on 31st August 2026				
• Glenmark Pharmaceuticals Ltd.	3.69%	ICICI Prudential Nifty Pharma Index Fund - Direct Plan - Growth				
• Alkem Laboratories Ltd.	3.08%	1 Year	3 Years	5 Years	10 Years	Since Inception
Biocon Ltd.	2.90%	-0.62	-0.77	-	-	-1.00
Zydus Lifesciences Ltd.	2.87%	ICICI Prudential Nifty Pharma Index Fund - Regular Plan - Growth				
IPCA Laboratories Ltd.	2.71%	1 Year	3 Years	5 Years	10 Years	Since Inception
Mankind Pharma Ltd.	2.70%	-1.42	-1.53	-	-	-1.78
Gland Pharma Ltd.	2.27%					
Sai Life Sciences Ltd.	1.99%					
Wockhardt Ltd.	1.54%					
Ajanta Pharma Ltd.	1.50%					
Piramal Pharma Ltd.	1.32%					
Abbott India Ltd.	1.31%					
Equity less than 1% of corpus						
Short Term Debt and net current assets	0.07%					
Total Net Assets	100.00%					

Top Sectors	
Healthcare	99.93%

• Top Ten Holdings

Top Sectors

Healthcare 99.93%

Benchmark

Nifty Pharma TRI

Quantitative Indicators


P/E : 42.09	P/B : 5.11	Dividend Yield : 0.52
Annual Portfolio Turnover Ratio : Equity - 0.30 times		Std Dev (Annualised) (3yrs): 15.94%
Sharpe Ratio : 0.97	Portfolio Beta : 1.00	Tracking Error : (1yr) 0.06% (3yr) 0.12%

The figures are not netted for derivative transactions.
Refer Disclaimer of NSE, BSE, NSE Indices Limited (NSE Indices) on page no. 138, respectively.
@@ Base Expense Ratio is as on the last business day of the month.
The Schemes do not offer any Plans/Options.
Fresh subscriptions in Income Distribution Cum Capital Withdrawal (IDCW) option through all modes such as Lump Sum mode (including Switches) and fresh registration of Systematic Investment Plan (SIP) and/or Systematic Transfer Plan (STP) registration (Target scheme), special products/features like Freedom SIP, SIP Top Up facility, Booster SIP, Flex STP, Booster STP, Capital Appreciation STP, in the scheme with effect from November 03, 2025
To Refer to the annexure for details on scheme objective, Index Methodology, IDCW history and SIP details. [Click here](#)

Riskometer

This product labelling is applicable only to the scheme

This Product is suitable for investors who are seeking*:
• Long term wealth creation solution
• An index fund that seeks to track returns by investing in a basket of Nifty Pharma Index stocks and aims to achieve returns of the stated index, subject to tracking error.



*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

ICICI Prudential Mutual Fund Corporate Office

ONE BKC, A - Wing, 13th Floor, Bandra-Kurla Complex, Mumbai 400 051, India.

Tel: 022 - 26525000 Fax: 022 - 26528100, website: www.icicipruamc.com, email id: enquiry@icicipruamc.com

Statutory Details & Risk Factors

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Disclaimer: In the preparation of the material contained in this document, the AMC has used information that is publicly available, including information developed in-house. Some of the material(s) used in the document may have been obtained from members/persons other than the AMC and/or its affiliates and which may have been made available to the AMC and/or to its affiliates. Information gathered and material used in this document is believed to be from reliable sources. The AMC however does not warrant the accuracy, reasonableness and / or completeness of any information. We have included statements / opinions / recommendations in this document, which contain words, or phrases such as "will", "expect", "should", "believe" and similar expressions or variations of such expressions, that are "forward looking statements". Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our services and / or investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices etc. ICICI Prudential Asset Management Company Limited (including its affiliates), the Mutual Fund, The Trust and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. Further, the information contained herein should not be construed as forecast or promise. The recipient alone shall be fully responsible/are liable for any decision taken on this material.